Literature DB >> 11193913

Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative.

J H Lee1, J M Lee, K H Lim, J K Kim, S K Ahn, Y J Bang, C I Hong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11193913     DOI： 10.1111/j.1749-6632.2000.tb07055.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  8 in total

Review 1.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  Allometric scaling of pegylated liposomal anticancer drugs.

Authors:  Whitney P Caron; Harvey Clewell; Robert Dedrick; Ramesh K Ramanathan; Whitney L Davis; Ning Yu; Margaret Tonda; Jan H Schellens; Jos H Beijnen; William C Zamboni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-08-24       Impact factor: 2.745

3.  Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.

Authors:  Whitney P Caron; John C Lay; Alan M Fong; Ninh M La-Beck; Parag Kumar; Suzanne E Newman; Haibo Zhou; Jane H Monaco; Daniel L Clarke-Pearson; Wendy R Brewster; Linda Van Le; Victoria L Bae-Jump; Paola A Gehrig; William C Zamboni
Journal:  J Pharmacol Exp Ther       Date:  2013-09-16       Impact factor: 4.030

4.  Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.

Authors:  Hong Li; Hyo-Eon Jin; Wooyoung Kim; Yong-Hae Han; Dae-Duk Kim; Suk-Jae Chung; Chang-Koo Shim
Journal:  Pharm Res       Date:  2008-07-25       Impact factor: 4.200

5.  Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.

Authors:  William C Zamboni; Suresh Ramalingam; David M Friedland; Robert P Edwards; Ronald G Stoller; Sandra Strychor; Lauren Maruca; Beth A Zamboni; Chandra P Belani; Ramesh K Ramanathan
Journal:  Clin Cancer Res       Date:  2009-02-03       Impact factor: 12.531

6.  Anticancer effects of CKD-602 (Camtobell®) via G2/M phase arrest in oral squamous cell carcinoma cell lines.

Authors:  Young-Kyun Kim; Na-Youn Koo; Pil-Young Yun
Journal:  Oncol Lett       Date:  2014-10-30       Impact factor: 2.967

7.  Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.

Authors:  Huali Wu; Ramesh K Ramanathan; Beth A Zamboni; Sandra Strychor; Suresh Ramalingam; Robert P Edwards; David M Friedland; Ronald G Stoller; Chandra P Belani; Lauren J Maruca; Yung-Jue Bang; William C Zamboni
Journal:  Int J Nanomedicine       Date:  2012-10-19

8.  A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.

Authors:  Hee Seung Kim; Sang-Yoon Park; Chan-Yong Park; Young Tae Kim; Beob-Jong Kim; Yong Jung Song; Byoung-Gie Kim; Yong Beom Kim; Chi-Heum Cho; Jong-Hyeok Kim; Yong Sang Song
Journal:  Br J Cancer       Date:  2020-09-30       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.